Phase 4 Glaucoma Trial, Recruiting NCT06848946 Sponsor: Glaukos Corporation Condition: Glaucoma
Back to Glaucoma

Phase 4 Glaucoma Trial, Recruiting

NCT06848946
Recruiting Phase 4

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You have a cataract in one eye that is significant enough to need cataract surgery (a procedure called phacoemulsification).
  • You have been diagnosed with either open-angle glaucoma (including certain types such as those related to protein buildup or pigment in the eye) or high eye pressure (without necessarily having glaucoma) in the eye that would have the cataract surgery.

Who may not be able to join:

  • You currently have active inflammation or swelling in the clear front part of your eye (the cornea).
  • You have a condition affecting the back of your eye (the retina) that is not related to glaucoma.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.

Contact this trial

Principal Investigator: Study Director, Glaukos Corporation

Phone: 949-739-8749

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 4
Sponsor
Glaukos Corporation
Registry
ClinicalTrials.gov
Start date
13 January 2025
Est. completion
1 August 2026

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Change from baseline in mean diurnal IOP

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov